scispace - formally typeset
C

Clement T. Loy

Researcher at University of Sydney

Publications -  102
Citations -  9438

Clement T. Loy is an academic researcher from University of Sydney. The author has contributed to research in topics: Dementia & Population. The author has an hindex of 34, co-authored 101 publications receiving 6762 citations. Previous affiliations of Clement T. Loy include Westmead Hospital & Garvan Institute of Medical Research.

Papers
More filters
Journal ArticleDOI

Global, regional, and national burden of neurological disorders, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016

Valery L. Feigin, +270 more
- 01 Nov 2017 - 
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors (GBD) study provides such information but does not routinely aggregate results that are of interest to clinicians specialising in neurological conditions as discussed by the authors.
Journal ArticleDOI

Global, regional, and national burden of neurological disorders during 1990-2015

Valery L. Feigin, +241 more
Journal ArticleDOI

Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016

Valery L. Feigin, +215 more
TL;DR: In 2016, the global lifetime risk of stroke from the age of 25 years onward was approximately 25% among both men and women, and there was geographic variation in the lifetime risk, with the highest risks in East Asia, Central Europe, and Eastern Europe.
Journal ArticleDOI

A meta-analysis of hippocampal atrophy rates in Alzheimer's disease.

TL;DR: A meta-analysis of hippocampal atrophy rates in AD patients and matched controls from studies reported in the peer-reviewed literature found that cohorts and methods used to determine such rates are heterogeneous, leading to differences in reported annualised rates.
Journal ArticleDOI

Galantamine for Alzheimer's disease and mild cognitive impairment.

TL;DR: Prolong release / once daily formulation of galantamine at 16 - 24mg/d was found to have similar efficacy and side-effect profile as the equivalent twice-daily regime, and Galantamine's safety profile in AD is similar to that of other cholinesterase inhibitors with respect to cholinergically mediated gastrointestinal symptoms.